Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.

¹ Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford OX3 7LD, UK. Electronic address: marc.feldmann@kennedy.ox.ac.uk.
² Imperial College London, London, UK.
³ Laterell Venture Partners, San Francisco, CA, USA.
⁴ Faculty of Medicine, Clinical and Experimental Sciences, Southampton General Hospital, Southampton, UK.
⁵ Trinity College, Cambridge, UK.
⁶ Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
⁷ Oxford Clinical Trials Research Unit, Botnar Research Centre, Oxford, UK.
⁸ Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.

No abstract available

MeSH terms